Rivaroxaban (BAY59-7939)
Sponsors
Bayer
Conditions
Atrial FibrillationPreventionThromboembolismVenous Thromboembolism
Phase 2
An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study
CompletedNCT00402467
Start: 2004-02-29End: 2004-11-30Updated: 2014-12-23
BAY59-7939, Japanese Phase II in Atrial FibrillationTrial Status
CompletedNCT00779064
Start: 2004-07-31End: 2005-06-30Updated: 2014-12-25
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
CompletedNCT00839826
Start: 2002-12-31End: 2003-11-30Updated: 2014-12-17
Phase 3
Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin
CompletedNCT00329628
Start: 2006-02-28End: 2007-03-31Updated: 2014-10-28
Regulation of Coagulation in Orthopedic Surgery to Prevent DVT and PE, a Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement
CompletedNCT00332020
Start: 2006-02-28End: 2007-06-30Updated: 2015-01-27
Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.
CompletedNCT00361894
Start: 2006-02-28End: 2007-01-31Updated: 2014-10-27
Dose-confirmatory Bridging Study in Total Hip Replacement
CompletedNCT01205932
Start: 2010-09-30End: 2011-08-31Updated: 2017-01-23
Dose-confirmatory Bridging Study in Total Knee Replacement
CompletedNCT01206972
Start: 2010-10-31End: 2011-06-30Updated: 2017-01-18